The lead compound RaxoneŽ/CatenaŽ (INN: idebenone) is being developed in four indications:
- Leber's Hereditary Optic Neuropathy, in preparation for regulatory re-submission in Europe
- Duchenne Muscular Dystrophy, in a Phase III study
- Primary Progressive Multiple Sclerosis, in a Phase II study conducted by the US National Institutes of Health
- MELAS syndrome, in a Phase II study conducted by the Columbia University of New York City
RaxoneŽ and CatenaŽ are trademarks of Santhera Pharmaceuticals for its proprietary idebenone 150 mg tablets.
For more information about the availability of CatenaŽ (idebenone) under Named Patient or other Special Access Programs outside the United States click here.
Santhera's second compound in clinical development, omigapil, is in preparation for a Phase I pharmacokinetics study in in pediatric patients with Congenital Muscular Dystrophy.
The third compound fipamezole for the treatment of Dyskinesia in Parkinson's Disease, is available for licensing of development and world-wide commercialization rights.